| Summary: | Iodine complexes have known antimicrobial properties along with reported <i>in-vitro</i> antiviral activity for several viruses. Renessans is one such product with iodine complexes and ascorbic acid. The present study was designed to determine its efficacy for SARS-CoV-2 in <i>Rhesus macaque</i>. <i>Rhesus macaque</i> were assigned to: A) prophylactic group (n = 3), (B) treatment group (n = 3), (C) infection control group (n = 4), and (D) negative control group (n = 4). Groups A, B, and C were challenged with 2 × 10<sup>6</sup> TCID of SARS-CoV-2. The prophylactic group (A) was administered Renessans from 5 days before infection till 8 days postinfection (DPI). The treatment group (B) was administered Renessans from 3 till 8 DPI. Group C was administered water-insoluble fractions only. Nasal swabs from all monkeys of groups A, B, and C remained positive for SARS-CoV-2 till 2 and 7 DPI, while the swabs became negative for groups A and B at 14 DPI. Likewise, fecal matter of monkeys in group A returned negative results during the experiment, while that of group B had significantly decreased viral load (10<sup>1.5</sup> genome copies/mL) compared to group C (10<sup>3</sup> genome copies/mL). Hence, it is concluded that Renessans has <i>in-vivo</i> SARS-CoV-2 activity and may result in early clearance of SARS-CoV-2.
|
|---|
